Psychedelic stocks echo cannabis bubble risks
The host cautioned that the current hype and valuation of psychedelic drug development stocks may mirror the disappointing investment trajectory of cannabis stocks.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.